搜索
©1994-2009ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.:2001-10-29:100126325(2001)0620547204,,(,221002):(NO)(NOS),mIL22R+,NADPH,NOS[(371440177)pmol/mg,(81730179)pmol/mg],,mIL22R+[mIL22R+(2318719),0],NOSDMA,NADPHNO:;;:R56212+5:ANO,,NONOSmIL22R+,NO1111NADPHNBTDMAOVASigma,L2arg,,NONOSmIL22R,IL26TNF112SD52,(25030)g,,[1]OVA1mg,5109,AL(OH)3100mg,21125%OVA,,20min,10DMAL2arg,30min,DMA014mg/kgL2arg300mg/kg11320min,1%30mg/kg,,NOIL26TNF,,100mg,40mmol/L4pH712019mL,10000r/min5min,50L,NONOS4%(1196kPa),4%2h,HE8mm8mm4mm,-208m,NADPHNADPH(Tris2HClNADPH1125mg,NBT0125mg),3725min,;ABC[2]mIL22R,400mIL22R+,114(xs),t2NO,NO/NONOS,L2arg(1)7452001121(6)BasicMedicalSciencesandClinics©1994-2009ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.(xs,n=8)GroupsNO-2/NO-3Serum(mol/L)Lungtissue(nmol/mg)LungNOS(pmol/mg)Control231751167012530101481730179Asthmagroup251001185111100116033714401773DMAgroup221252149012320100981140163L2arggroup2612511671186101140342147017133P0101vscontrolL2argIL26TNF,NOSDMANO(2)2IL6TNFTable2LevelsofIL26TNFintheratsera(xs,n=8)GroupsIL26(ng/L)TNF(ng/L)Control918831605512532141Asthmagroup207175351073358175701743DMAgroup5518871736117530188L2arggroup2901505215533921506111233P0101vscontrol,(),,,,(1)mIL22R+,DMAmIL22R+,(3,2)3mIL22R+Table3NumbersofmIL22Rpositivelymphocyteintheratssubmucose(xs,n=5)GroupsmIL22R+(cell/HP)Control0Asthmagroup2318719DMAgroup711216L2arggroup25158131Fig1Manyinfiammatroycellswereseenroundrespiratroybronchioleofasthmaticrats,alveolusseptumwasswelledremarkably(HE,250)2Fig2ThenumbersofmIL22Rpositivelymphocytesweresignificantlyincreasedinabronchialsubmucoseaofasthmaticrats(immunohisto2chemicalmethod,450)NADPHL2arg,,DMA(4,3,4)845BasicMedicalSciencesandClinics2001121(6)©1994-2009ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.(n=5)Groupsbronchialsmoothmusclebloodves2selsmoothbronchialepitheli2umbloodvesselendotheliumalveolusseptumControl+++Asthmagroup+++++++++DMAgroupL2arggroup++++++++++++darkblue;++blue;+lightblue;nocolor3,NADPHFig3BronchialepithelialcellsofasthmaticratswerethebestpositivebyNADPHhistochemicalmethod(histochemicalmethod,1000)4,NADPHFig4AlveolusseptumofasthmaticratwerethebestpsitivebyNADPHhistochemicalmethod(histo2chemicalmethod,1000)3NO,,NO,NO,NO[3]NOSDMA,NO;NOSL2arg,NO,NONONO,Fumitochinose[4],NO,,NONADPHNOS,,L2argNOS,,,NOS,NO,,,NO,,,[5],NO,DNA[6]mIL22R+,L2arg,;DMAmIL22R+,:,mIL22R+,IL21IL26TNF,,;NO,IL21IL26TNF,NO,,NO,mIL22R+,NO[7]:,9452001121(6)BasicMedicalSciencesandClinics©1994-2009ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.[1],,,.[J].,1998,18(1):72-77.[2],.[M].:,1998.116-119.[3]BrennerBM,TroyJL,BallermannBJ.Endotheium2dependentvascularresposes,mediatorsandmethanisms[J].JClinIn2vest,1989,84:1373-1378.[4]FumitochinoseE,ChristopheD,WilliamE,etal.Prolongedpulmonaryvasodilatoractionofinhalednitricoxidebyzaprinastinawakelambs[J].JApplPhysial,1995,78:1288-1295.[5]BamesPJ.Nitricoxideandairways[J].EuxRespirJ,1993,6:163[6],.[M].:,1997.6-26.[7]BarnesPJ,LiewFY.Nitricoxideandasthmaticinflammation[J].ImmunolToday,1995,16:128-130.DistributionofnitricoxidesynthaseintheratasthmamodellungtissuesXIAOPeng2nian,MOLiu2qin,GAOFeng2guang(DepartmentofMicrobiology,XuzhouMedicalCollege,XuzhouJiangsu221002,China)Abstract:Toinvestigatetheroleofnireicoxide(NO)inbronchialasthma,histochemicalandimmunohistochemicalmethodswereusedtofindthedistributionofnitricoxidesynthase(NOS)intheratasthmamodelandthechangesofmembraneinterleukin22receptorpositivelymphocytes.NADPHwasfoundtobeahistochemicalmarkerwhichreflectingNOSactivity.MeanwhiletherewasanobviousincreaseofNOSactivityinasthmaticrataswellasinalveolarseptum.TheNOSlevelofasthmaticratwasfarmorethanthatofcontrol[asthmaticgroup(37.440.77)pmol/mg,controlgroup(8.730.79)pmol/mg].AirwayinflammatorycellnumbersofasthmaticratswereincreasedandmIL22Rpositivelym2phocytesweresignificantlyincreased(asthmaticgroup23.87.9vscontrolgroupnil),butlowerintheDMAgroup.NOwastheinflammatoryeffectormoleculeofasthmaticrat.Keywords:nitricoxide;asthma;rat(546)MCP-1,,p21,,,,;;,,:,;;,QTICD,,,:;;;2,progress;INSIGHT,(),(2003)(2005)055BasicMedicalSciencesandClinics2001121(6)